View More Recent Stories
-
Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer
-
Pharvaris (PHVS) Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE
-
Pharvaris (PHVS) Provides Business Update, Expands Development Program for Deucrictibant
-
Pharvaris B.V. (PHVS) PT Raised to $38 at Oppenheimer
